Knights of Columbus Asset Advisors’s Biogen BIIB Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,660	Closed	-$1.22M	–	408
2024 Q1	$1.22M	Hold	5,660	–	–	0.09%	235
2023 Q4	$1.46M	Buy	5,660 +2,800	+98%	+$688K	0.09%	246
2023 Q3	$735K	Buy	+2,860	New	+$765K	0.07%	252
2021 Q2	–	Sell	-2,274	Closed	-$636K	–	302
2021 Q1	$636K	Buy	2,274 +74	+3%	+$20K	0.06%	257
2020 Q4	$539K	Sell	2,200 -8,029	-78%	-$2.07M	0.06%	276
2020 Q3	$2.9M	Buy	10,229 +2,132	+26%	+$595K	0.36%	97
2020 Q2	$2.17M	Hold	8,097	–	–	0.27%	117
2020 Q1	$2.56M	Buy	8,097 +7,437	+1,127%	+$2.26M	0.32%	88
2019 Q4	$196K	Sell	660 -3,684	-85%	-$1.02M	0.02%	347
2019 Q3	$1.01M	Buy	+4,344	New	+$1.01M	0.38%	76

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Knights of Columbus Asset Advisors's BIIB Position: Q2 2024 in Review

Knights of Columbus Asset Advisors sold out of Biogen (BIIB) in Q2 2024, closing a stake of 5,660 shares — an estimated $1.22M sold.

Knights of Columbus Asset Advisors first reported a position in BIIB in Q3 2019 and held it in 10 quarters. The position peaked at $2.9M in Q3 2020. 944 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Knights of Columbus Asset Advisors reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 5,660 Biogen shares in Q2 2024, an estimated $1.22M.
Knights of Columbus Asset Advisors first reported a position in Biogen in Q3 2019 and held it in 10 quarters.
Knights of Columbus Asset Advisors's Biogen position peaked at $2.9M in Q3 2020.
944 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.